A vaccine with low efficacy is better than no vaccine at all
For the seventeenth time, Congo finds itself at the center of an Ebola crisis — and the world, once again, finds itself without a perfect answer. The WHO convened an emergency session this week in Geneva, confronting a strain of the virus for which no approved vaccine exists, spreading through a region where delayed testing allowed it to move unseen for weeks. What is unfolding is a familiar human tragedy made newly urgent: the tension between the slow work of science and the fast logic of contagion, playing out across borders, bodies, and communities that cannot afford to wait.
- Congo's 17th Ebola outbreak is spreading faster than detection systems could track, with testing shortages giving the virus weeks of invisible momentum before authorities could respond.
- The WHO's emergency meeting forced a hard choice onto the table: deploy experimental vaccines with low efficacy against this strain, or watch the outbreak outpace every other available tool.
- Neighboring countries sealed their borders almost immediately, and the US imposed travel restrictions — decisions that may slow the virus but have already collapsed the daily economies of border communities in Congo.
- An American missionary who tested positive is being evacuated to a high-security German facility, signaling how seriously international authorities are treating the risk of the virus crossing into new continents.
- The shadow of 2018 hangs over every decision — that outbreak lasted two years and killed 2,300 people, and officials know that number represents not a worst case, but simply what happened last time.
The World Health Organization called an emergency meeting this week to confront Congo's 17th Ebola outbreak — one spreading faster than expected, and for which no effective vaccine currently exists. WHO Director-General Tedros Adhanom spoke from Geneva about his alarm at both the scale and speed of transmission. The virus had been circulating for weeks before detection, a delay caused by a shortage of tests. By the time it was identified, it had already taken hold across the region.
The emergency session centered on a difficult question: whether to deploy experimental vaccines designed for a related strain, even knowing their efficacy against this variant is low. Richard Hatchett of the Coalition for Epidemic Preparedness Innovation acknowledged that pushing forward with candidates still in study phases had become necessary. The clock, he made clear, was already running.
The human cost became visible almost immediately. Neighboring countries including Rwanda closed their border crossings — a decision that, while medically defensible, meant sudden economic collapse for Congolese families who depended on cross-border work to survive. A motorcycle taxi driver in the region described the desperation: people with jobs on the other side of the border now had nothing.
The United States restricted entry from the affected region and arranged the evacuation of an American missionary who tested positive — flying him on a specialized medical aircraft to a high-security isolation facility in Germany, known for its capacity to manage hemorrhagic fevers at the highest containment level.
What remains is a race between a fast-moving virus and an imperfect global response. The memory of 2018 — two years, 2,300 deaths — is not a worst-case warning for officials watching this outbreak. It is simply the record of what happened last time.
The World Health Organization called an emergency meeting this week to confront a problem it has faced seventeen times before in Congo, and never quite solved: another Ebola outbreak, spreading faster than anyone expected, with no vaccine that works against the strain now circulating.
Tedros Adhanom, the WHO's director-general, spoke from Geneva about his alarm at both the scale and speed of transmission. The virus had been moving through the region for weeks before anyone caught it—a delay born from the simple fact that there weren't enough tests. By the time detection came, the damage was already spreading. Ebola destroys the immune system and triggers hemorrhagic fever. It travels through direct contact with the blood and bodily fluids of the infected, or through contaminated clothing. Once it takes hold, it moves fast.
The last major outbreak in Congo, in 2018, burned for two years and killed 2,300 people. This one arrived with a different urgency. The WHO convened its emergency session on Tuesday to discuss a difficult option: deploying experimental vaccines designed for a known strain of the virus, even though their effectiveness against this new variant remains low. Richard Hatchett, who directs the Coalition for Epidemic Preparedness Innovation, made clear that accelerating vaccine development—pushing forward with candidates still in study phases—had become necessary. The clock was running.
The human geography of the crisis became immediately apparent. Neighboring countries, including Rwanda, sealed their border crossings. For families in Congo who depend on work across those borders just to eat, the closure meant sudden economic collapse. A motorcycle taxi driver in the region described the immediate desperation: people who had jobs on the other side of the line now had nothing. The fear that the virus might breach the borders of Central Africa altogether had put health authorities across the continent into maximum alert.
The United States moved quickly to restrict entry from the affected region. An American missionary working in Congo tested positive for the virus. Rather than treat him locally, U.S. authorities arranged his evacuation on a specialized medical aircraft to a high-security isolation ward in Germany—a facility with an international reputation for managing hemorrhagic fevers and the infrastructure to contain transmission at the highest level. The decision reflected both the severity of his condition and the determination to prevent the virus from entering American territory.
What unfolds now is a race between a virus that moves through populations and the machinery of global health response that must move faster. The experimental vaccines exist but are imperfect. The borders are closing. The economic damage is immediate. And somewhere in the calculation of every health official watching this outbreak is the memory of 2018, and the knowledge that 2,300 deaths is not a worst-case scenario—it is simply what happened last time.
Citações Notáveis
Tedros Adhanom expressed concern about the scale and speed of transmission, citing heavy population movement in the region— WHO Director-General Tedros Adhanom
Richard Hatchett stated that accelerating vaccine development for candidates still in study phases has become necessary— Richard Hatchett, Coalition for Epidemic Preparedness Innovation
A Conversa do Hearth Outra perspectiva sobre a história
Why did it take weeks to detect this outbreak when Congo has dealt with Ebola seventeen times before?
Testing capacity. The infrastructure to identify cases quickly just isn't there. By the time they confirmed what they were seeing, the virus had already moved through communities.
And the vaccines they're discussing—why use something that doesn't work well against this particular strain?
Because they have nothing else. A vaccine with low efficacy is better than no vaccine at all when people are dying. It's a choice made under pressure, not a choice anyone would make in calmer circumstances.
The border closures—that seems like it would stop the spread, right?
It stops the virus from crossing, maybe. But it also stops the people who depend on crossing to survive. You're containing disease and creating hunger at the same time.
Why send the American missionary to Germany instead of treating him in Congo?
The German facility has isolation wards built specifically for this—maximum containment, the expertise, the equipment. Congo's hospitals are overwhelmed. It's not about American privilege; it's about where the best chance of survival exists.
What happens if the experimental vaccines don't slow transmission?
Then you're watching the 2018 scenario repeat, maybe worse. Two years. Thousands dead. And this time, the fear is that it doesn't stay contained to Congo.